首页> 外文期刊>Saudi Pharmaceutical Journal >Formulation and evaluation of ileo-colonic targeted matrix-mini-tablets of Naproxen for chronotherapeutic treatment of rheumatoid arthritis
【24h】

Formulation and evaluation of ileo-colonic targeted matrix-mini-tablets of Naproxen for chronotherapeutic treatment of rheumatoid arthritis

机译:萘普生回肠结肠靶向性微型片剂的制备和评价用于类风湿关节炎的慢性治疗

获取原文
获取外文期刊封面目录资料

摘要

In this present research work, the aim was to develop ileo-colonic targeted matrix-mini-tablets-filled capsule system of Naproxen for chronotherapeutic treatment of Rheumatoid Arthritis. So Matrix-mini-tablets of Naproxen were prepared using microsomal enzyme dependent and pH-sensitive polymers by direct compression method which were further filled into an empty HPMC capsule. The compatibility was assessed using FT-IR and DSC studies for pure drug, polymers and their physical mixtures. The prepared batches were subjected to physicochemical studies, drug content estimation, in-vitro drug release and stability studies. When FTIR and DSC studies were performed, it was found that there was no interaction between Naproxen and polymers used. The physicochemical properties of all the prepared matrix-mini-tablets batches were found to be in limits. The drug content percentage in the optimized formulation F18 was found to be 99.24+/-0.10%. Our optimized matrix-mini-tablets-filled-capsule formulation F18 releases Naproxen after a lag time of 2.45+/-0.97h and 27.30+/-0.86%, 92.59+/-0.47%, 99.38+/-0.69% at the end of 5, 8, 12h respectively. This formulation was also found to be stable as per the guidelines of International Conference on Harmonisation of Technical Requirements of Pharmaceuticals for Human Use. Thus, a novel ileo-colonic targeted delivery system of Naproxen was successfully developed by filling matrix-mini-tablets into an empty HPMC capsule shell for targeting early morning peak symptoms of rheumatoid arthritis.
机译:在这项当前的研究工作中,目标是开发纳普生的回肠结肠靶向微胶囊填充胶囊系统,用于类风湿关节炎的慢性治疗。因此,使用微粒体酶依赖性和pH敏感的聚合物通过直接压片法制备了萘普生的微型基质片,并将其进一步填充到空的HPMC胶囊中。使用FT-IR和DSC研究评估了纯药物,聚合物及其物理混合物的相容性。将制备的批次进行理化研究,药物含量估算,体外药物释放和稳定性研究。当进行FTIR和DSC研究时,发现萘普生与所用聚合物之间没有相互作用。发现所有制备的基质-迷你片剂批次的理化性质均处于极限。发现优化制剂F18中的药物含量百分比为99.24 +/- 0.10%。我们优化的基质-迷你片剂填充胶囊制剂F18在滞后时间为2.45 +/- 0.97h和27.30 +/- 0.86%,92.59 +/- 0.47%,99.38 +/- 0.69%的滞后时间后释放萘普生分别为5、8、12小时。根据国际人用药品技术要求统一会议的指南,也发现该制剂是稳定的。因此,通过将基质微型片剂填充到空的HPMC胶囊壳中以靶向风湿性关节炎的清晨高峰症状,成功开发了萘普生的新型回肠结肠靶向递送系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号